Search results for: Health Care Systems
Filter search results
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
…international value assessment from countries with very different health care systems and opportunity costs. Reference pricing also overlooks the issue of confidential price negotiations between the pharmaceutical industry and individual…
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…pharmaceuticals deliver to society in the long run, it is also necessary, at a minimum, to account for any medical cost offsets they generate in health care systems. The…
OHE is Pleased to Announce the Appointment Two New Economists: Marina Rodes Sanchez and Chris Sampson
12 October 2017
…the economics of health care systems in emerging markets. As part of her MSc Marina undertook a summer research placement at OHE, where she studied whether and to what extent…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…of the antibiotic. Value for money also means it should minimise the financial burden on health care systems to get the required antibiotics. De-link revenue from volume to allow for…
How to Analyse EQ-5D Data? Methods for Analysing and Reporting EQ-5D Data: The Indispensable New Guide
8 December 2020
…recently – in routine data collection in health care systems. (…) EQ-5D has become the cornerstone of health technology appraisal (HTA), affecting important decisions about access to new medicines. But despite…
The Impact of Health Technology Assessment on Drug Development
3 January 2009
…important snapshot of current industry perspectives on the impact of HTA. Responses show that the pharmaceutical industry is adjusting to the realities of today’s cost conscious health care systems by…
Hospital Acquired Infection
8 January 1997
…primary and secondary care. Given that many health care systems are changing, that lengths of stay are shrinking and that financial accountability is both more transparent and more stringent, it…
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
…are taking control over the decision-making threshold itself. As elected representatives, arguably, they should: the threshold ought to reflect societal priorities and preferences—not only for health gain, but also for…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…Institute for Health Economics (IHE) in Sweden shows that health systems and societies in general (consumers) were able to appropriate most of the life-cycle value (surplus) generated by SGAs in…